Disorders of clotting and coagulation are common in the intensive care unit. Diagnosis, treatment and monitoring of these disorders are traditionally based on conventional coagulation tests such as activated partial thromboplastin time (APTT) and international normalised ratio (InR). We present here a patient who developed massive postoperative haemorrhage secondary to an acquired factor VIII inhibitor. The case highlights the utility and sensitivity of thromboelastography (TEG) in the diagnosis of the condition and monitoring the response to therapy.
Patients admitted to the intensive care unit (ICU) may present with, or develop disordered coagulation. The most common of these include coagulopathy associated with anticoagulant therapy, disseminated intravascular coagulopathy, heparin induced thrombotic thrombocytopenia and coagulopathy associated with liver failure, trauma and massive haemorrhage.
Traditionally, intensive care clinicians have used prothrombin time, international normalised ratio, activated partial thromboplastin time (APTT), fibrinogen levels and platelet count to evaluate coagulopathy and the response to management.
Whilst thromboelastography (TEG ® ) is not a new test, its ability to functionally assess coagulation is becoming increasingly appreciated in intensive care medicine. We present a case of recurrent acute haemorrhage, secondary to an acquired factor VIII (FVIII) inhibitor that was successfully treated with recombinant factor VIIa (FVIIa), high dose steroids and cyclophosphamide with the guidance of TEG. We highlight that TEG provided a more dynamic and sensitive assessment of in vivo clotting than traditional coagulation tests.
CASE SUMMARY
A 61-year-old previously well post-menopausal female was referred to a co-located women's hospital for management of suspected endometrial cancer. She presented a week earlier to a rural hospital with significant per vaginal bleeding and profound anaemia (Hb 33 g/l), requiring transfusions with 10 units of packed red blood cells prior to inter-hospital transfer.
At the co-located women's hospital, she underwent a diagnostic dilatation and curettage and subsequently went on to have a total abdominal hysterectomy with bilateral salpingo-oophorectomy for grade 1 endometrial carcinoma. This second procedure was complicated by postoperative bleeding which manifested as multi-focal haematomas, including a 6.8 cm pelvic haematoma, 7.8cm rectus sheath haematoma and bilateral retroperitoneal haematomas. This was managed with the administration of a further 10 units of packed red blood cells and 5 units of fresh frozen plasma.
The postoperative course was also complicated by anuric renal failure requiring renal replacement therapy, hypercapnic respiratory failure requiring non-invasive ventilation and on-going bleeding from a previous central venous catheter site. Throughout this period, the only abnormality on her coagulation studies was an isolated, mild elevation of the APTT that ranged from 38 to 46 seconds (normal range 22 to 38 seconds), with no preoperative coagulation studies being performed. Treatment for the suspected bleeding coagulopathy consisted of local pressure to the wound site and commencement of tranexamic acid 500 mg three-times daily.
The patient was transferred to our ICU for further invasive monitoring and treatment. An abdominal computerised tomogram revealed an increase in the size of all haematomas ( Figure 1 ). TEG performed at the bedside revealed a profoundly abnormal result, with absence of clot formation at >120 minutes ( Figure 2 ). Conventional coagulation tests revealed a normal international normalised ratio (1.1) and prothrombin time (13 seconds). However, there was a worsening prolongation of the APTT to 68 seconds, which failed to correct with mixing studies. Further testing identified an acquired FVIII deficiency, with a FVIII value of 2% (normal range 50 to 150%) with inhibitor present in high titre (128 Bethesda units). It was suspected that this was a para-neoplastic phenomenon. The modest increase in APTT did not appear to be consistent with the degree of haemorrhage and our clinical impression was that the TEG parameters indicated a more severe coagulopathy. Initial treatment of ongoing haemorrhage was continuing the tranexamic acid and the addition of three-factor prothrombinex ® (CSl ltd, 2013; VIC, Aus) in an attempt to avoid use of recombinant FVIIa 1 .
Immunosuppression in the form of hydrocortisone and intravenous cyclophosphamide 400 mg weekly was also commenced. The patient was initially haemodynamically stable, requiring only ongoing transfusion of one to two units of packed red blood cells per day but subsequently developed hypovolaemic shock three days after admission. Accordingly, recombinant FVIIa (9 mg) was administered every two hours and the patient underwent interventional radiological guided arterial embolisation of the right T12, l1 and l3 segmental arteries.
During the first 48 hours, serial coagulation studies and heparinase TEGs (Haemonetics) were performed. The APTT decreased from a peak of 69 to a nadir of 34 (Table 1) and was normal during the period of life-threatening haemorrhage that necessitated commencement of recombinant FVIIa therapy. over the same time course, there was a progressive improvement in the α angle, R-time and k-time of the TEG, though the TEG parameters were still abnormal at the time of further haemorrhage ( Table 1) . A clinical decision was made to use TEG to guide response to recombinant FVIIa therapy, which would otherwise have de-escalated in view of the improving APTT. over a 19-day period, FVIII inhibitor levels declined to 2 Bethesda units and the FVIII level increased to 50%, consequently the recombinant FVIIa therapy was ceased. This was associated with a progressive improvement in all the TEG parameters (Table 1) . At one month post diagnosis the patient achieved remission, with an undetectable FVIII inhibitor level, a sustained FVIII level >70% and no further bleeding. Cyclophosphamide was ceased and steroid therapy was subsequently weaned.
DISCUSSIon
We have presented an uncommon case of a spontaneously acquired idiopathic FVIII inhibitor causing massive postoperative haemorrhage. Despite the presence of severe bleeding, there was initially only a modest increase in the APTT, originally thought to be a coagulopathy in the context of postoperative haemorrhage. The severely abnormal TEG was more in keeping with the severity of the ongoing haemorrhage and subsequent laboratory studies permitted diagnosis of the FVIII inhibitor. As recombinant FVIIa therapy has a relatively short half-life (three to six hours), it is likely that variations in timing of TEG acquisition affected TEG parameters. Baseline TEG revealed a severe clotting abnormality and subsequent changes in TEG parameters were more sensitive, responsive to treatment and quicker to obtain than the traditional tests of coagulation. Thus, APTT changed little with therapy and resolution of haemorrhage, but changes in TEG parameters were larger and more dynamic.
Acquired FVIII inhibitors occur in the context of congenital haemophilia in patients who have received multiple transfusions of FVIII concentrate. However, patients can rarely develop inhibitors de novo with an incidence ranging between one to four million/ year 2, 3 . Acquired Haemophilia A is associated with solid organ 4 and haematological malignancies 2 , preexisting autoimmune conditions 5 and pregnancy 6 , with 50% of diagnoses labeled idiopathic 3 . The mortality associated with this condition is up to 20% 7,8 and more than 85% of patients have life-threatening bleeds at some stage of their disease process 8 .
The characteristic abnormality found on the routine coagulation tests performed on patients with acquired FVIII inhibitors is a prolonged APTT that does not correct with mixing with normal plasma, as was the case in the patient described here. The presence and titre of inhibitor is measured by the Bethesda and Nijmegen modification assays. These assays provide confirmation of diagnosis and long-term response to treatment but do not fully correlate to their risk of bleeding [9] [10] [11] . Clot formation is a continuous process that may be better studied in a global haemostasis assay, such as TEG or thromboelastometry.
TEG has been used to monitor the response of haemorrhage to treatment with recombinant FVIIa in patients with congenital haemophilia who develop inhibitors, in a non-bleeding setting 9, 10, 12 .
In a single centre study of acquired haemophilia, thromboelastomatory parameters monitored during TEG evaluates the visco-kinetic properties of a blood clot to provide information on coagulation and fibrinolysis. It is thought to reflect global haemostasis more effectively than other traditional coagulation tests 14, 15 . The TEG generates a trace from which four values: R-time, k-value, the α angle and maximum amplitude can be calculated, which reflect various phases of clot formation and resolution. In our patient the R-time decreased and α angle improved with administration of recombinant FVIIa, indicating a decrease in time to initiate clot formation and increased overall clot strength. The information provided by the TEG appeared to be a more sensitive guide to coagulation status than the APTT both at the time of diagnosis, when the APPT was only minimally prolonged, and during therapy. The TEG is available in a more readily available time frame than measurement of the inhibitor with the Bethesda assay, which has a poor clinical correlation. TEG was also useful as a daily bedside test in the ICU in guiding treatment impact as improvements occurred with the administration of recombinant FVIIa.
The use of TEG in the ICU is increasing. It has been shown to increase the accuracy of blood product administration during the perioperative management of patients undergoing cardiac surgery 16 and liver transplantation 17, 18 . In sepsis-associated disseminated intravascular coagulation, TEG has been shown to aid diagnosis in neonates but further studies in adults have not been as convincing [19] [20] [21] .
In patients with the coagulopathy of chronic liver disease, there is increasing recognition of the limitation of traditional tests of coagulation in the assessment of bleeding and thrombotic risk 22 . In cirrhotic patients, TEG may provide a better guide in assessing blood product replacement in acute haemorrhage and prior to invasive interventions 22 . There is also increasing evidence for the beneficial role of TEG testing in the management of traumaassociated coagulopathy 23, 24 and in surgical associated massive transfusion. A recent Cochrane review found no mortality difference but decreased blood loss and decreased blood product administration using TEG 25 .
ConClUSIon
Thromboelastography is increasingly recognised as a useful and cost-effective point-of-care test to rapidly assess abnormalities of clotting in the ICU. This case illustrates its usefulness in a life threatening coagulopathy. Further research into its role in the other clotting disorders such as disseminated intravascular coagulation, sepsis and liver disease is required.
